FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Carcinoma|HER2-Positive Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|HER2-positive Breast Cancer
Interventions: DRUG: Anastrozole|DRUG: Denifanstat|DRUG: Exemestane|DRUG: Fulvestrant|PROCEDURE: Echocardiography|DRUG: Letrozole|DRUG: Paclitaxel|BIOLOGICAL: Trastuzumab|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Biospecimen Collection|PROCEDURE: Biopsy
Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)